Subscribe to news

Press Center

08.05.2013
The Human Stem Cells Institute, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, announced its consolidated results for 2012 under IFRS
30.04.2013
The Human Stem Cells Institute held a public presentation of the company’s strategy and business plan for the period from 2013 to 2017.
30.04.2013
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, announced its plans for a roadshow for the purpose of attracting an institutional investor.
25.04.2013
The Human Stem Cells Institute, today announced the decision of the Company’s Board of Directors on convocation of the Annual General Shareholders’ Meeting upon the results of 2012.
03.04.2013
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its audited unconsolidated results for 2012 in accordance with the Russian Accounting Standards (RAS)
26.03.2013
Human Stem Cells Institute OJSC (“HSCI”, MICEX: ISKJ), one of the leading Russian biotech companies, today announced that an agreement has been signed to supply the Russian pharmaceutical company Sotex Pharm Firm with the innovative drug Neovasculgen®, developed by HSCI for treatment of Peripheral Arterial Disease.
07.03.2013
OJSC, one of the leading Russian biotech companies, today announced the decision of its Board of Directors on the lists of candidates to the Board of Directors and the Audit Commission of the Company to be elected at the Annual General Shareholders’ Meeting.
28.02.2013
Human Stem Cells Institute, one of the leading Russian biotech companies, today announced that on February 26, 2013, the Ministry of Healthcare of Ukraine issued marketing authorization to HSCI for Neovasculgen®, a drug intended for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI).
02.11.2012
Human Stem Cells Institute OJSC, one of Russia’s leading biotech companies, today announced its unaudited results for the first nine months of 2012 in accordance with Russian Accounting Standards (RAS)
21.09.2012
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announced that certification of Neovasculgen’s first batches has been completed and the drug will go to market before the end of September.